Inventiva reports preliminary financial results for Full-Year 2022¹
14 févr. 2023 16h00 HE
|
INVENTIVA
Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...
Infant Bacterial Therapeutics AB (publ) Bokslutskommuniké 1 januari – 31 december 2022
10 févr. 2023 02h00 HE
|
Infant Bacterial Therapeutics AB
VD kommenterar Under de sista tre månaderna av 2022 var rekryteringen av prematura spädbarn till vår omfattande fas 3 studie betydligt bättre än vad den var under motsvarande period de föregående...
Infant Bacterial Therapeutics AB (publ) Interim report January 1- December 31, 2022
10 févr. 2023 02h00 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO The speed of recruitment of preterm infants into our large phase 3 study significantly increased in the final three months of 2022 compared to the corresponding period in...
Infant Bacterial Therapeutics publicerar Årsredovisning för 2021 i XHTML format
27 janv. 2023 08h55 HE
|
Infant Bacterial Therapeutics AB
Den 31 mars 2022 publicerade IBT sin årsredovsning för 2021. Filformatet som då användes var PDF. Idag publicerar IBT samma rapport i XHTML format. Innehållet i rapporten har inte ändrats. se...
Infant Bacterial Therapeutics publishes Annual Report for 2021 in XHTML format
27 janv. 2023 08h55 HE
|
Infant Bacterial Therapeutics AB
On March 31 2022 IBT published the 2021 annual report in the format of a PDF file. Today, IBT publish the same report in the XHTML format. The content of the report has not been changed. see...
Interim Financial Report Third quarter ended 30 September 2022
30 nov. 2022 02h30 HE
|
Jøtul AS
YTD Q3 2022, the Jotul Group reached a consolidated profit of MNOK 4.5 (YTD Q3 2021: loss of MNOK 57.5). The operating profit totaled MNOK 95.5 in YTD Q3 2022 (YTD Q3 2021: MNOK 12.9). The 2022 total...
Castellum, Inc. Announces Strong Third Quarter Financial Results Including Record Revenue
15 nov. 2022 06h55 HE
|
Castellum, Inc.
BETHESDA, Md., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, data analytics, software, and IT services company focused...
Inventiva publie ses informations financières du 3ème trimestre 2022¹
10 nov. 2022 16h00 HE
|
INVENTIVA
Position de trésorerie2 à 72,6 M€ au 30 septembre 2021 , sans prise en compte du paiement de 12,6 M$ reçu le 4 novembre de la part de Sino BiopharmChiffre d’affaires de 0,1 M€ sur les neuf premiers...
Inventiva reports 2022 Third Quarter Financial Information¹
10 nov. 2022 16h00 HE
|
INVENTIVA
Cash position2 at €72.6m as of September 30, 2022, not including the $12.6 million upfront payment received from Sino Biopharm on November 4, 2022Revenues of €0.1m for the first nine months of 2022 ...
Infant Bacterial Therapeutics AB (publ) (IBT), delårsrapport 1 juli – 30 september 2022
10 nov. 2022 02h00 HE
|
Infant Bacterial Therapeutics AB
VD kommenterar Vårt utvecklingsprojekt IBP-9414 i klinisk fas III fortskrider väl, och som jag tidigare nämnt arbetar vi med flera aktiviteter för att påskynda genomförandet av vår studie. Det är...